93245-98-8

Basic information

• Product Name: 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde
• Synonyms: 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde;1,4-Dioxaspiro[4.5]decane-8-carboxaldehyde
• CAS NO: 93245-98-8
• Molecular Formula: C₉H₁₄O₃
• Molecular Weight: 170.20566
• Mol File: 93245-98-8.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 268.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde(93245-98-8)
• EPA Substance Registry System: 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde(93245-98-8)

Safety Data

• Hazardous Substances Data: 93245-98-8(Hazardous Substances Data)

Usage

General Description

1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde is a chemical compound that belongs to the class of aldehydes. It is a spiro compound, meaning it contains a bicyclic structure with a bridgehead carbon. The chemical structure of 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde consists of a cyclohexane ring fused to a dioxane ring, with an aldehyde group attached to the carbon at the bridgehead position. 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde is used in organic synthesis and as a building block for the preparation of various heterocyclic compounds. It has potential applications in pharmaceutical and agrochemical industries due to its unique structure and reactivity. Additionally, 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde may also find use as a fragrance ingredient in the perfume industry.

Upstream product

• 50-00-0 formaldehyd 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 654674-38-1 2,4,6-triisopropyl-N'-(1,4-dioxaspiro[4.5]decan-8-ylidene)benzenesulfonohydrazide 
• 72445-22-8 1,4-dioxaspiro[4.5]dec-7-ene-8-carbaldehyde 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 79-37-8 oxalyl dichloride 
• 67-68-5 dimethyl sulfoxide 
• 59691-19-9 1-Methoxy-4-(hydroxymethyl)-1,4-cyclohexadiene 
• 63579-89-5 triethyl pentane-1,3,5-tricarboxylate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 3618-03-9 methyl 4-hydroxycyclohexanecarboxylate 

Downstream Products

• 96184-81-5 (+/-)-cyclohexanone-4-carboxaldehyde 
• 1187964-14-2 ethyl 3-{1,4-dioxaspiro[4.5]decan-8-yl}propanoate 
• 58012-66-1 3-(4-oxocyclohexyl)propionic acid ethyl ester 

Relevant articles and documents

DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.